GlassScriptPhysician profile
Taylor C Valdetero
NPI 1407252315
$3,650.03
in general payments reported to CMS, 2019-2025
31 companies · $623 in 2025
The $623 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $862 · 2022: $868 · 2023: $827 · 2024: $470 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,920.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,920.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $930.82 | 2021-2025 | |
| Lilly USA, LLC | $390.98 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $277.18 | 2021-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $198.71 | 2022-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $190.07 | 2021-2025 | Breztri, Lokelma, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $189.64 | 2021-2023 | Jardiance, Synjardy |
| Ironwood Pharmaceuticals, INC | $165.20 | 2021-2024 | Linzess |
| Amgen INC. | $118.30 | 2021-2024 | Repatha, Otezla |
| Astellas Pharma US INC | $114.48 | 2021-2024 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $107.91 | 2021-2023 | Verquvo, Steglatro, Belsomra |
| Esperion Therapeutics, INC. | $107.19 | 2021-2025 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $104.08 | 2022-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $103.88 | 2022-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.49 | 2023-2025 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $86.02 | 2021-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $77.18 | 2023-2025 | Cologuard Collection Kit |
| Tolmar, INC. | $43.94 | 2025 | Jatenzo |
| Phathom Pharmaceuticals, INC. | $39.96 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $38.72 | 2023 | Shingrix, Arexvy |
| Antares Pharma, INC. | $32.79 | 2025 | Xyosted |
| Janssen Pharmaceuticals, INC | $32.56 | 2021 | |
| Axsome Therapeutics, INC. | $27.90 | 2025 | Auvelity |
| Corcept Therapeutics | $26.78 | 2022 | |
| Pfizer INC. | $23.65 | 2023 | |
| Tandem Diabetes Care, INC. | $22.06 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Daiichi Sankyo INC. | $20.57 | 2021 | |
| Biogen, INC. | $18.75 | 2021 | |
| Insulet Corporation | $18.70 | 2024 | Omnipod |
| Biohaven Pharmaceuticals, INC. | $18.52 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.04 | 2023 | |
| Acella Pharmaceuticals, LLC | $13.96 | 2025 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Valdetero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.